Get the Stockscreener App
24.70
0.06%
0.0148
Elanco Animal Health Inc stock is traded at $24.70, with a volume of 2.24M.
It is up +0.06% in the last 24 hours and up +0.84% over the past month.
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, poultry, and swine production.
See More
Previous Close:
$24.69
Open:
$24.79
24h Volume:
2.24M
Relative Volume:
0.40
Market Cap:
$12.34B
Revenue:
$4.89B
Net Income/Loss:
$-242.00M
P/E Ratio:
-50.52
EPS:
-0.489
Net Cash Flow:
$315.00M
1W Performance:
-1.18%
1M Performance:
+0.84%
6M Performance:
+5.26%
1Y Performance:
+67.15%
1-Day Range:
$24.43
$25.33
1-Week Range:
$23.73
$25.33
52-Week Range:
$13.39
$27.72
Elanco Animal Health Inc Stock (ELAN) Company Profile
Name
Elanco Animal Health Inc
Sector
Phone
877-352-6261
Address
450 ELANCO CIRCLE, INDIANAPOLIS
Compare ELAN vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELAN
Elanco Animal Health Inc
|
24.70 | 12.33B | 4.89B | -242.00M | 315.00M | -0.489 |
TAK
Takeda Pharmaceutical Co Adr
|
16.64 | 52.93B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.72 | 42.94B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.02 | 38.71B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
75.02 | 31.48B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
552.11 | 23.53B | 3.17B | 1.29B | 1.01B | 27.09 |
Elanco Animal Health Inc Stock (ELAN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-26 | Initiated | Citigroup | Buy |
| Jan-22-26 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-09-25 | Initiated | Barclays | Overweight |
| Nov-21-25 | Initiated | KeyBanc Capital Markets | Overweight |
| Nov-19-25 | Upgrade | Argus | Hold → Buy |
| Oct-07-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-17-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jun-26-25 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-09-24 | Initiated | UBS | Buy |
| Dec-02-24 | Initiated | Leerink Partners | Market Perform |
| Sep-19-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-05-24 | Upgrade | Stifel | Hold → Buy |
| Dec-19-23 | Initiated | Jefferies | Buy |
| Dec-15-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-07-23 | Initiated | Exane BNP Paribas | Outperform |
| Apr-20-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Aug-18-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-16-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-21-22 | Downgrade | Goldman | Buy → Sell |
| Jul-12-22 | Initiated | Piper Sandler | Neutral |
| Nov-18-21 | Initiated | Morgan Stanley | Overweight |
| Oct-28-21 | Downgrade | Stifel | Buy → Hold |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Jun-15-21 | Upgrade | Cleveland Research | Underperform → Neutral |
| May-11-21 | Upgrade | Barclays | Underweight → Equal Weight |
| May-11-21 | Upgrade | Gabelli & Co | Hold → Buy |
| Apr-15-21 | Initiated | Stifel | Buy |
| Mar-22-21 | Downgrade | Gabelli & Co | Buy → Hold |
| Feb-26-21 | Upgrade | Credit Suisse | Neutral → Outperform |
| Dec-09-20 | Downgrade | Argus | Buy → Hold |
| Nov-09-20 | Downgrade | Barclays | Overweight → Underweight |
| Aug-20-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-13-20 | Resumed | Credit Suisse | Neutral |
| Aug-04-20 | Resumed | Goldman | Buy |
| Jul-27-20 | Downgrade | Cleveland Research | Neutral → Underperform |
| Apr-02-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-10-20 | Initiated | Raymond James | Mkt Perform |
| Dec-19-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Nov-07-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-23-19 | Initiated | Barclays | Overweight |
| Aug-26-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Aug-15-19 | Upgrade | UBS | Sell → Neutral |
| May-23-19 | Initiated | Guggenheim | Neutral |
| Mar-18-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Mar-13-19 | Resumed | Morgan Stanley | Equal-Weight |
| Feb-12-19 | Initiated | William Blair | Mkt Perform |
| Jan-23-19 | Initiated | UBS | Sell |
| Jan-15-19 | Initiated | Argus | Buy |
| Oct-15-18 | Initiated | Morgan Stanley | Equal-Weight |
View All
Elanco Animal Health Inc Stock (ELAN) Latest News
Elanco Confirms Date and Conference Call for Second Quarter 2026 Financial Results Announcement - Barchart.com
Integrated Advisors Network LLC Purchases New Position in Elanco Animal Health Incorporated $ELAN - MarketBeat
Strs Ohio Grows Position in Elanco Animal Health Incorporated $ELAN - MarketBeat
SG Americas Securities LLC Reduces Stock Position in Elanco Animal Health Incorporated $ELAN - MarketBeat
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Elanco Animal Health - TMX Newsfile
NYSE: ELAN Lawsuit Alert: Investors who lost money with Elanco A - GuruFocus
Elanco Animal Health Inc (NYSE:ELAN) Technical Breakout Setup Scores 10/10 Technical Rating and 9/10 Setup Quality - ChartMill
Form 4 Elanco Animal Health For: 2 July By Investing.com - Investing.com Nigeria
Elanco (ELAN) executive awarded 25,620 stock options at $24.09 strike price - Stock Titan
Elanco (ELAN) director converts cash fees into 584 deferred stock units - Stock Titan
Form 4 Elanco Animal Health For: 30 June By Investing.com - Investing.com Canada
Elanco (NYSE: ELAN) executive receives new deferred stock unit award - Stock Titan
Elanco (ELAN) CEO Jeffrey Simmons receives 115 deferred stock units grant - Stock Titan
Elanco (NYSE: ELAN) CFO gets new deferred stock unit award - Stock Titan
Elanco Commits To Supporting US In Fight Against Screwworm - InkFreeNews.com
Is the Options Market Predicting a Spike in Elanco Animal Health Stock? - Yahoo Finance
Enterprise value to EBIT forward of Elanco Animal Health Incorporated – NYSE:ELAN - TradingView
Piper Sandler reiterates Elanco stock rating on defensive positioning By Investing.com - Investing.com Canada
Piper Sandler Maintains Elanco Animal Health(ELAN.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Price to sales forward of Elanco Animal Health, Inc. – MUN:5EA - TradingView
Price to earnings forward of Elanco Animal Health Incorporated – NYSE:ELAN - TradingView
Enterprise value to EBITDA forward of Elanco Animal Health Incorporated – NYSE:ELAN - TradingView
Enterprise value to revenue forward of Elanco Animal Health Incorporated – NYSE:ELAN - TradingView
Louisiana State Employees Retirement System Buys New Shares in Elanco Animal Health Incorporated $ELAN - MarketBeat
Elanco Animal Health Inc (ELAN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Elanco working to manage parasitic fly’s arrival in U.S. - Indianapolis Business Journal
OP Asset Management Ltd Makes New Investment in Elanco Animal Health Incorporated $ELAN - MarketBeat
Elanco Animal Health Inc (ELAN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Elanco Animal Health, Inc. Actuals & Estimates (NYSE:ELAN) - TradingView
ELAN Forecast — Price Target — Prediction for 2027 - TradingView
Is Elanco Animal Health Incorporated (ELAN) Positioned for Long-Term Growth With Seven Potential Blockbuster Launches? - Yahoo Finance
Friedenthal Financial Acquires New Holdings in Elanco Animal Health Incorporated $ELAN - MarketBeat
Leading Veterinary Medicine Market Players Driving Innovation - SNS Insider
Argus Research Maintains Elanco Animal Health(ELAN.US) With Buy Rating - Moomoo
A Look at Elanco Animal Health Inc (ELAN) After 3.0% Decline -- GF Value $15.57 vs Price $23.18 - GuruFocus
Credelio from Elanco Animal Health Inc.soft chew once a month against ticks and fleas - AD HOC NEWS
Pet Healthcare Spending Is Soaring. These Stocks Are Positioned to Clean Up - AOL.com
Elanco To Launch $25 Million Corporate Venture Capital Platform - Pulse 2.0
Neurizon, Elanco Ink Long-Term Supply Agreement for Human Health Monepantel - Contract Pharma
T. Rowe Price Investment Management Inc. Increases Position in Elanco Animal Health Incorporated $ELAN - MarketBeat
Elanco Animal Health Incorporated (NYSE:ELAN) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
ELAN Maintained by TD Cowen -- Price Target Raised to $32 - GuruFocus
ELANElanco Animal Health Inc Stock Price and Quote - Finviz
Elanco to launch $25M VC program focused on animal health innovation - Inside INdiana Business
Elanco Ventures Expands Animal Health Innovation Ecosystem - Kalkine Media
Elanco (ELAN) Launches Venture Capital Platform for Animal Healt - GuruFocus
Veterinary API Manufacturing Market to Reach USD 18.48 Billion by 2035 as Animal Health Investments and Zoonotic Disease Prevention Accelerate – SNS Insider - GlobeNewswire Inc.
TD Cowen Issues Positive Forecast for Elanco Animal Health (NYSE:ELAN) Stock Price - MarketBeat
Elanco Animal Health Is Maintained at Buy by TD Cowen - Moomoo
TD Cowen raises Elanco Animal Health price target on product launches - Investing.com Canada
Elanco Animal Health Incorporated Establishes Elanco Ventures Corporate Venture Capital Platform - marketscreener.com
Elanco Animal Health Inc Stock (ELAN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.20%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):